Niagen Bioscience Inc

Niagen Bioscience Inc(NAGE)股票分析

$2.105

-0.347 (-16.47%)收盤時

Loading chart…
最高
2.340
開盤
2.320
成交量加權均價
2.16
成交量
1.30M
市值
—
最低
2.050
成交金額
2.82M
企業價值/稅息折舊攤銷前利潤(TTM)
23.23

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen, directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities.

AI 分析 of Niagen Bioscience Inc (NAGE)

持有

Currently, Niagen Bioscience, Inc. (NAGE) is trading at $2.40, significantly below its 52-week high of $7.95, which presents a potential buying opportunity. However, the stock has a low RSI of 38.77, indicating it may be oversold, but it also reflects a lack of strong buying momentum. The forward P/E ratio is 16.67, suggesting that the stock is relatively valued compared to its earnings potential. The main risk is the declining performance in its ingredient business due to increased competition, which could impact future revenue growth.

估值指標

Niagen Bioscience Inc(NAGE)目前預期本益比為 17.15,5 年平均預期本益比為 39.86。

預期本益比

合理
5 年均值 P/E
39.86
目前P/E
17.15
高估
66.13
低估
13.58

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
30.23
目前EV/EBITDA
23.23
高估
43.26
低估
17.20

預期股價營收比

低估
5 年均值 P/S
3.45
目前P/S
1.22
高估
5.30
低估
1.60

Alphio AI 對 NAGE 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%NAGE

$14.51

情境價格

基

基準

基準 · 50%NAGE

$12.61

情境價格

悲

悲觀

悲觀 · 25%NAGE

$10.88

情境價格

持有 NAGE 的大戶

S

SteelPeak Wealth, LLC

+ 持有NAGE

-5.42%

3個月報酬率

事件時間軸

2026-11-04 (ET)

16:30:00

Rob Fried: Q3 Revenue $27.2M, Outlook for Growth in 2027

16:30:00

Company Expects E-commerce Revenue Growth of 5%-20% in 2026

2026-10-22 (ET)

09:00:00

Niagen Bioscience Launches Prescription-Only Injection Kit

2026-10-20 (ET)

09:00:00

Niagen Bioscience Launches New Tru Niagen Skincare Category

2026-10-01 (ET)

09:00:00

Niagen Bioscience Launches New Brand Campaign

資訊

NAGE 常見問題 —— 由 Alphio AI 解答

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen, directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities. It operates in the Healthcare sector.

Currently, Niagen Bioscience, Inc. (NAGE) is trading at $2.40, significantly below its 52-week high of $7.95, which presents a potential buying opportunity. However, the stock has a low RSI of 38.77, indicating it may be oversold, but it also reflects a lack of strong buying momentum. The forward P/E ratio is 16.67, suggesting that the stock is relatively valued compared to its earnings potential. The main risk is the declining performance in its ingredient business due to increased competition, which could impact future revenue growth.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易